Management of pituitary tumors is multidisciplinary, with medical therapy playing an increasingly important role. With the exception of prolactin-secreting tumors, surgery is still considered the first-line treatment for the majority of pituitary adenomas. However, medical/pharmacological therapy plays an important role in controlling hormone-producing pituitary adenomas, especially for patients with acromegaly and Cushing disease (CD). In the case of non-functioning pituitary adenomas (NFAs), pharmacological therapy plays a minor role, the main objective of which is to reduce tumor growth, but this role requires further studies. For pituitary carcinomas and atypical adenomas, medical therapy, including chemotherapy, acts as an adjuvant to surgery and radiation therapy, which is often required to control these aggressive tumors. In the last decade, knowledge about the pathophysiological mechanisms of various pituitary adenomas has increased, thus novel medical therapies that target specific pathways implicated in tumor synthesis and hormonal over secretion are now available. Advancement in patient selection and determination of prognostic factors has also helped to individualize therapy for patients with pituitary tumors. Improvements in biochemical and “tumor mass” disease control can positively affect patient quality of life, comorbidities and overall survival. In this review, the medical armamentarium for treating CD, acromegaly, prolactinomas, NFA, and carcinomas/aggressive atypical adenomas will be presented. Pharmacological therapies, including doses, mode of administration, efficacy, adverse effects, and use in special circumstances are provided. Medical therapies currently under clinical investigation are also briefly discussed.

Citations

Citations to this article as recorded by  

• Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
  Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee
  Endocrinology and Metabolism.2023; 38(5): 463.     CrossRef
• PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling
  Jingdian Liu, Junwen Wang, Weidong Tian, Yu Xu, Ran Li, Kai Zhao, Chao You, Yuan Zhu, Joerg Walter Bartsch, Hongquan Niu, Huaqiu Zhang, Kai Shu, Ting Lei
  Aging.2022; 14(15): 6066.     CrossRef
• LncRNA MYMLR promotes pituitary adenoma development by upregulating carbonyl reductase 1 via sponging miR-197-3p
  Tuo Wang, Ping Mao, Yan Zhang, Bo Cui, Mao-De Wang, Ya Li, Ke Gao
  Anti-Cancer Drugs.2022; 33(10): 1058.     CrossRef
• Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas
  Carolina Carrillo-Najar, Daniel Rembao-Bojórquez, Martha L. Tena-Suck, Sergio Zavala-Vega, Noemí Gelista-Herrera, Miguel A. Ramos-Peek, Juan L. Gómez-Amador, Febe Cazares-Raga, Fidel de la Cruz Hernández-Hernández, Alma Ortiz-Plata
  Diagnostics.2021; 11(2): 330.     CrossRef
• Recent Understanding and Future Directions of Recurrent Corticotroph Tumors
  José Miguel Hinojosa-Amaya, César Ernesto Lam-Chung, Daniel Cuevas-Ramos
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• What to Do with Incidentally Discovered Pituitary Abnormalities?
  Fabienne Langlois, Maria Fleseriu
  Medical Clinics of North America.2021; 105(6): 1081.     CrossRef
• Aggressive prolactinoma (Review)
  Ana Valea, Florica Sandru, Aida Petca, Mihai Dumitrascu, Mara Carsote, Razvan-Cosmin Petca, Adina Ghemigian
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Diagnosis and Treatment of Pituitary Adenomas
  O. A. Beylerli, Zhao Shiguang, I. F. Gareev, Chen Xin
  Creative surgery and oncology.2020; 9(4): 311.     CrossRef
• Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery
  Cristina Capatina, José Miguel Hinojosa-Amaya, Catalina Poiana, Maria Fleseriu
  Expert Review of Endocrinology & Metabolism.2020; 15(5): 321.     CrossRef
• Modern principles of the diagnosis and conservative treatment of Cushing disease
  Ashraf Abdali, Ludmila Astafeva, Pavel Kalinin, Yuriy Trunin, I. V. Chernov, G. E. Сhmutin, Abdali Badshahzar, GulSharif Sherzad, Simfukwe Keith
  Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery).2020; (10): 67.     CrossRef
• Effects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line
  Jung Soo Lim, Young Woo Eom, Eun Soo Lee, Hyeong Ju Kwon, Ja-Young Kwon, Junjeong Choi, Choon Hee Chung, Young Suk Jo, Eun Jig Lee
  Endocrinology and Metabolism.2019; 34(3): 302.     CrossRef
• Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
  Domenico Solari, Rosario Pivonello, Chiara Caggiano, Elia Guadagno, Carmela Chiaramonte, Giovanni Miccoli, Luigi M. Cavallo, Marialaura Del Basso De Caro, Annamaria Colao, Paolo Cappabianca
  World Neurosurgery.2019; 127: 695.     CrossRef
• Expression of Cyclin E/Cdk2/p27Kip1 in Growth Hormone Adenomas
  Wei Dong, Haibo Zhu, Hua Gao, Wenjian Shi, Yu Zhang, Hongyun Wang, Chuzhong Li, Guidong Song, Yazhuo Zhang
  World Neurosurgery.2019; 121: e45.     CrossRef
• Acromegaly
  Annamaria Colao, Ludovica F. S. Grasso, Andrea Giustina, Shlomo Melmed, Philippe Chanson, Alberto M. Pereira, Rosario Pivonello
  Nature Reviews Disease Primers.2019;[Epub]     CrossRef
• Differenzialdiagnostik und Therapie der Hypophysenadenome
  M. Hlaváč, F. Sommer, G. Karpel-Massler, R. Wirtz, T. Hoffmann, A. Paľa
  HNO.2019; 67(4): 307.     CrossRef
• Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
  José Miguel Hinojosa-Amaya, Daniel Cuevas-Ramos, Maria Fleseriu
  Drugs.2019; 79(9): 935.     CrossRef
• Aggressive and Malignant Prolactinomas
  Nicoleta Cristina Olarescu, Luis G. Perez-Rivas, Federico Gatto, Thomas Cuny, Maria A. Tichomirowa, Gianluca Tamagno, Manuel D. Gahete
  Neuroendocrinology.2019; 109(1): 57.     CrossRef
• New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A
  Mariana Fuertes, Julieta Tkatch, Josefina Rosmino, Leandro Nieto, Mirtha Adriana Guitelman, Eduardo Arzt
  Frontiers in Endocrinology.2018;[Epub]     CrossRef
• Prenatal alcohol exposure increases the susceptibility to develop aggressive prolactinomas in the pituitary gland
  Shaima Jabbar, Kenneth Reuhl, Dipak K. Sarkar
  Scientific Reports.2018;[Epub]     CrossRef
• Aggressive and malignant pituitary tumours: state-of-the-art
  Dorota Dworakowska, Ashley B Grossman
  Endocrine-Related Cancer.2018; 25(11): R559.     CrossRef
• Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto
  Maria Isabel Ocampo Navia, Juan Carlos Gómez Vega, Oscar Hernando Feo Lee
  Universitas Médica.2018;[Epub]     CrossRef
• Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway
  Junwen Wang, Zhuo Zhang, Ran Li, Wei Sun, Juan Chen, Huaqiu Zhang, Kai Shu, Ting Lei
  Life Sciences.2018; 194: 150.     CrossRef
• Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers
  Danyang Shen, Xiaoming Yu, Yan Wu, Yuanlei Chen, Gonghui Li, Feng Cheng, Liqun Xia
  Expert Review of Anticancer Therapy.2018; 18(5): 487.     CrossRef
• New Molecular Targets for Treatment of Cushing’s Disease
  Elizabeth Foulkes, John Newell-Price
  Endocrinology and Metabolism Clinics of North America.2018; 47(2): 367.     CrossRef
• Pituitary-Directed Therapies for Cushing’s Disease
  Fabienne Langlois, Jennifer Chu, Maria Fleseriu
  Frontiers in Endocrinology.2018;[Epub]     CrossRef
• Updates in Diagnosis and Treatment of Acromegaly
  Roula Zahr, Maria Fleseriu
  European Endocrinology.2018; 14(2): 57.     CrossRef
• Root cause analysis of diagnostic and surgical failures in the treatment of suspected Cushing’s disease
  Hasan A. Zaidi, David L. Penn, David J. Cote, Edward R. Laws
  Journal of Clinical Neuroscience.2018; 53: 153.     CrossRef